Proffitt & Goodson’s Sagimet Biosciences SGMT Stock Holding History

Proffitt & Goodson’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-175	Closed	-$1.33K	–	448
2025 Q2	$1.33K	Buy	+175	New	+$739	﹤0.01%	252

Other funds holding SGMT

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Proffitt & Goodson's SGMT Position: Q3 2025 in Review

Proffitt & Goodson sold out of Sagimet Biosciences (SGMT) in Q3 2025, closing a stake of 175 shares — an estimated $1.33K sold.

Proffitt & Goodson first reported a position in SGMT in Q2 2025 and held it in 1 quarter. The position peaked at $1.33K in Q2 2025. 72 funds tracked by Wall St. Rank hold SGMT as of Q3 2025.

Proffitt & Goodson reported no remaining Sagimet Biosciences position as of Q3 2025 after selling out during the quarter.
Proffitt & Goodson sold 175 Sagimet Biosciences shares in Q3 2025, an estimated $1.33K.
Proffitt & Goodson first reported a position in Sagimet Biosciences in Q2 2025 and held it in 1 quarter.
Proffitt & Goodson's Sagimet Biosciences position peaked at $1.33K in Q2 2025.
72 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2025.

Based on Proffitt & Goodson's 13F filing for Q3 2025, filed 21 Oct 2025.